Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.1852W HIGH $31.73
Volume
1.86 M
Value Traded
26.21 M
Short % Float
16.25%
-5.55%Week
-18%1 Month
-20.46%3 Month
+2.36%6 Month
-10.78%5 Year
+17.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.03 B
EPS (TTM)
-3.61
P/E Ratio
-
Ent. Value
2.36 B
Total Shares
127.33 M
Float Shares
84.98 M
Insiders
33.26%
Institutions
68.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RCUS Catalyst Timeline
Dated clinical, regulatory and corporate events for Arcus Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arcus Biosciences, Inc.
317Total events
19Upcoming
88Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationAB102Trial
First-in-human healthy volunteer study of AB102 expected to initiate this month
atopic dermatitis and chronic spontaneous urticariasource ↗
▲Partnership / LicenseCorporate
Clinical trial collaboration to evaluate casdatifan + ivonescimab in ccRCC
clear cell renal cell carcinoma (ccRCC)source ↗
◆Trial InitiationcasdatifanTrial
Planned initiation of casdatifan + ivonescimab cohort in ARC-20
clear cell renal cell carcinoma (ccRCC)source ↗
◆PublicationcasdatifanPresentation
Research published in Nature linking clinical activity with HIF-2a biology in advanced kidney cancer patients treated with Casdatifan
advanced kidney cancersource ↗
▲Milestone PaymentcasdatifanCorporate
Arcus to receive $15M milestone payment from Taiho triggered by PEAK-1 enrollment in Japan
clear cell renal cell carcinomasource ↗
▲PublicationcasdatifanPresentation
ARC-20 casdatifan monotherapy results published in Nature
advanced clear cell renal cell carcinomasource ↗
◆Oral PresentationPresentation
Participation in Goldman Sachs 47th Annual Global Healthcare Conference
▲Partnership / LicensecasdatifanCorporate
Clinical trial collaboration and supply agreement to evaluate casdatifan in combination with PD-L1/VEGF-A bispecific immunomodulator
kidney cancersource ↗
▲EU Orphan DesignationQuemliclustatEx-US Regulatory
EMA granted orphan drug designation to quemliclustat for pancreatic cancer
pancreatic cancersource ↗
●Oral PresentationAB102Presentation
Preclinical data for AB102 presented in oral presentation at Society for Investigative Dermatology Annual Meeting
atopic dermatitis and chronic spontaneous urticariasource ↗
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan+cabozantinib cohort expected in mid-2026
IO-experienced ccRCCsource ↗
◆Poster PresentationcasdatifanPresentation
Poster presentation of new efficacy and biomarker data for casdatifan at ASCO GU 2026
metastatic clear cell renal cell carcinomasource ↗
▲Oral PresentationcasdatifanPresentation
Updated data from ARC-20 dose-escalation and expansion cohorts presented at ASCO GU
clear cell renal cell carcinoma (ccRCC)source ↗
▼Trial DiscontinuedDomvanalimabDiscontinuedTrial
Discontinuation of Phase 3 studies of domvanalimab plus zimberelimab in NSCLC due to futility
non-small cell lung cancer (NSCLC)source ↗
◆Quarterly UpdateCorporate
Q4 and Full-Year 2025 Financial Results and Pipeline Update Conference Call
▲Full ResultscasdatifanClinical Data
Updated efficacy analysis with DCO January 30, 2026
metastatic clear cell renal cell carcinomasource ↗
◆Topline ReadoutcasdatifanClinical Data
Additional analyses from late-line monotherapy cohorts expected in 1H 2026
late-line ccRCCsource ↗
▲Oral PresentationQuemliclustatPresentation
Data from ARC-9 Phase 2 study of quemliclustat plus gemcitabine/nab-paclitaxel presented at ASCO GI
pancreatic cancersource ↗
◆Trial InitiationAB801Trial
Advancement into expansion cohorts in NSCLC expected in H2 2025
non-small cell lung cancersource ↗
●Enrollment MilestonecasdatifanTrial
Enrollment completion expected for early-line cohorts by end of 2025
early-line ccRCCsource ↗
▲Oral PresentationDomvanalimabDiscontinuedPresentation
OS data from Arm A1 presented at ESMO 2025
upper gastrointestinal adenocarcinomassource ↗
▲Full ResultscasdatifanClinical Data
Pooled analysis of four monotherapy cohorts: mPFS 12.2 months, 18-month landmark PFS 43%
late-line clear cell renal cell carcinoma (ccRCC)source ↗
▲PublicationDomvanalimabDiscontinuedPresentation
EDGE-Gastric data published in Nature Medicine
upper gastrointestinal adenocarcinomassource ↗
▲Partnership / LicensecasdatifanCorporate
Taiho exercised option for exclusive license in Japan and certain Asian territories
clear cell renal cell carcinomasource ↗
◆Oral PresentationPresentation
Fireside chat at Morgan Stanley 23rd Annual Global Healthcare Conference
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Fireside chat at Citi's 2025 Biotech Back to School Conference
▲Enrollment CompleteQuemliclustatTrial
Enrollment completed for PRISM-1 Phase 3 trial of quemliclustat in first-line metastatic pancreatic ductal adenocarcinoma
first-line metastatic pancreatic ductal adenocarcinomasource ↗
▲Full ResultscasdatifanClinical Data
Prior efficacy and safety analysis with DCO August 15, 2025
metastatic clear cell renal cell carcinomasource ↗
▲Trial InitiationcasdatifanTrial
eVOLVE-RCC02 Phase 1b/3 study initiated
first-line metastatic ccRCCsource ↗
▲Orphan Drug DesignationQuemliclustatDesignation
FDA Orphan Drug Designation granted for quemliclustat
pancreatic cancersource ↗
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan monotherapy cohorts expected
ccRCC (IO-experienced, post anti-PD-1 and TKI)source ↗
▲Enrollment CompleteQuemliclustatTrial
Enrollment completion expected for PRISM-1
first-line metastatic pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationcasdatifanPresentation
Updated Phase I/Ib data presented at ASCO 2025
metastatic kidney cancersource ↗
▼Program DiscontinuationEtrumadenantDiscontinuedCorporate
Arcus and Gilead agreed not to pursue Phase 3 for etrumadenant; Gilead returned license
third-line metastatic colorectal cancersource ↗
◆Trial InitiationcasdatifanTrial
Initiation of clinical study evaluating casdatifan plus volrustomig in IO-naive ccRCC
clear cell renal cell carcinoma (ccRCC)source ↗
▲FDA Feedback ReceivedEtrumadenantDiscontinuedFDA Meeting
FDA feedback on registrational path for etrumadenant in third-line mCRC
third-line metastatic colorectal cancer (mCRC)source ↗
▲Oral PresentationcasdatifanPresentation
New clinical data from ARC-20 presented at ASCO GU 2025
clear cell renal cell carcinomasource ↗
▲First Patient DosedQuemliclustatTrial
First patient dosed in Japan by Taiho for PRISM-1 in February 2025
pancreatic cancersource ↗
▼Equity OfferingCorporate
Stock offering to fund casdatifan development after Gilead passed on option
◆Topline ReadouttiragolumabClinical Data
Roche expects Phase III readout for tiragolumab in esophageal cancer
esophageal cancersource ↗
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan monotherapy cohorts in patients progressed on anti-PD-1 and TKI
clear cell renal cell carcinoma (ccRCC)source ↗
◆Topline ReadoutDomvanalimabDiscontinuedClinical Data
Overall survival data from EDGE-Gastric study for domvanalimab plus zimberelimab and chemotherapy
upper gastrointestinal adenocarcinomassource ↗
Past FDA Catalysts and PDUFA Decisions
How RCUS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Domvanalimab | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C55 / 100
Pipeline Score
$2.1B
Pipeline Value
Overvalued
Valuation Signal
10
Drugs Scored
0.7x
rNPV / MCap
Top 11%
Small Cap(rank 73 of 658)
Percentile Rank
Arcus Biosciences, Inc. carries a moderate pipeline score (55/100), with $3.5B risk-adjusted pipeline value, led by Etrumadenant in Prostate Adenocarcinoma (Phase 2), across $133B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Etrumadenant Small moleculeNCT03821246 | Prostate Adenocarcinoma | Phase 2 | RECRUITING | 68 | Apr 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every RCUS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| casdatifan | clear cell renal cell carcinoma (ccRCC) | 2026-09-22 | 30 patients with a median follow-up of approximately 11 months; 43 patients with a minimum of 18 months and a median of approximately 21 months of follow-up; 121 patients in the pooled monotherapy cohorts, with median follow-up of approximately 28 monthsRead More | Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Azoy AlexanderOfficer (Chief Accounting Officer) | Option | 2,827 42,408 held | $15.44 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RCUS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.2 % (100 %) | 36.03 M | 1.17 M | 64.15% ( 456.75 K) |
RCUS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RCUS ranks across every disease it competes in
Competitive Position is a premium feature
See how RCUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRCUS News
RCUSArcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences has granted stock options to four new employees, allowing them to purchase a total of 21,200 shares at an exercise price of $26.39. This move is part of the company's strategy to attract talent and incentivize performance. The grants reflect the company's ongoing commitment to growth and development in the biopharmaceutical sector.
Read more →RCUSArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences is set to host an investor event on October 20, 2026, in New York City. The event will feature new data from the ARC-20 platform study, which evaluates casdatifan as a treatment for kidney cancer across multiple lines of therapy. This highlights the company's commitment to advancing cancer treatment options.
Read more →RCUSArcus Biosciences to Participate in Three Upcoming Investor Conferences
Arcus Biosciences announced its participation in three investor conferences scheduled for September 2026. The management team will engage with investors at these events, highlighting the company's focus on developing differentiated therapies for cancer and autoimmune diseases. This participation reflects the company's commitment to transparency and investor relations.
Read more →RCUSArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported its financial results for the second quarter of 2026, showcasing a strong performance. The company also provided an update on its clinical pipeline, emphasizing its commitment to developing innovative therapies for cancer and autoimmune diseases. A recent publication in Nature further underscores their research efforts.
Read more →RCUSArcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Arcus Biosciences has entered into a clinical supply agreement with AVEO Oncology to assess the efficacy of casdatifan, a small-molecule HIF-2α inhibitor, in combination with tivozanib for patients with advanced kidney cancer. This collaboration aims to explore innovative treatment options for this patient population.
Read more →RCUSArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences and Summit Therapeutics have announced a clinical trial collaboration to evaluate the efficacy of casdatifan combined with ivonescimab in treating kidney cancer. This partnership aims to leverage their respective strengths in developing innovative cancer therapies. The trial seeks to address significant unmet medical needs in oncology.
Read more →RCUSArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences will hold a conference call on August 5, 2026, to discuss its second-quarter financial results and updates on its drug pipeline. The call is scheduled for 1:30 PM PT / 4:30 PM ET. This event will provide stakeholders with important insights into the company's performance and future directions.
Read more →RCUSNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
A new study published in Nature discusses the relationship between clinical activity and HIF-2a biology in advanced kidney cancer patients treated with Casdatifan. This research may provide insights into the efficacy of Casdatifan in this patient population. Further details about the findings and implications are yet to be disclosed.
Read more →RCUSArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences has announced a clinical trial collaboration and supply agreement to evaluate Casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator for treating kidney cancer. This collaboration aims to explore the efficacy of this combination therapy in clinical settings. Further details on the trial design and expected outcomes were not disclosed.
Read more →RCUSArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Arcus Biosciences is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is a significant gathering for industry leaders and stakeholders. Further details about their presentation or topics of discussion have not been disclosed in the article.
Read more →RCUSArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences has reported its financial results for the first quarter of 2026 and provided an update on its pipeline. The article highlights the company's ongoing efforts in drug development and financial performance. However, specific details regarding the financial results and pipeline advancements are not disclosed in the text.
Read more →RCUS▲ +7.8%on this news
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences will host a conference call on May 5, 2026, to discuss its first-quarter financial results and pipeline updates. The call will provide insights into the company's progress in developing therapies for cancer and autoimmune diseases. Investors can join via phone or online, with a replay available post-event.
Read more →RCUS▲ +6%on this news
Arcus Biosciences Announces New Employment Inducement Grants - March 24, 2026
Arcus Biosciences has granted employment inducement equity awards to two new employees, totaling 7,050 stock options and 3,550 restricted stock units. The options were priced at $21.41 per share, reflecting the closing price on March 23, 2026. These awards were made under the company's 2020 Inducement Plan, approved by the Board of Directors.
Read more →About Arcus Biosciences, Inc.
Headquarters3928 POINT EDEN WAY, HAYWARD, CA, 94545
BIOPHARMAWATCH ELITE PLUS
Trade the next RCUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime